Clinical Study of OR for Second-line Treatment of Refractory MZL

This study tests a combination of obutinib (a BTK inhibitor) and rituximab (an anti-CD20 antibody) as a second-line treatment for marginal zone lymphoma (MZL) — a slow-growing type of B-cell blood cancer that has returned or stopped responding to prior treatment. **You may be eligible if...** - You are 18 to 80 years old with a confirmed diagnosis of marginal zone lymphoma - Your lymphoma has returned or was not controlled after at least one prior treatment - You have measurable disease on imaging - Your blood counts, heart, liver, and kidney function are adequate **You may NOT be eligible if...** - Your lymphoma has previously failed to respond to the same drug combination being tested - You have lymphoma involving the brain or spinal cord - You have significant heart problems - You have active hepatitis B, C, or HIV - You have had an organ transplant or bone marrow transplant - You have had major surgery within 6 weeks of starting the study Talk to your doctor to see if this trial is right for you.